Tag «recurrent ovarian cancer»

Mirvetuximab soravtansine-gynx

It’s only fair to share… Mirvetuximab soravtansine-gynx FDA 11/14/2022, To treat patients with rTo treat patients with recurrent ovarian cancer that is resistant to platinum therapy that is resistant to platinum therapy, Elahere FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer https://www.biochempeg.com/article/315.html 4846-85a8-48171ab38275 FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer November 15, 2022 Kristi …